VanEck Associates
NTLA icon

VanEck Associates’s Intellia Therapeutics NTLA Stock Holding History

VanEck Associates’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$59K Sell
4,622
-769
-14% -$9.8K ﹤0.01% 1327
2025
Q4 		$48K Buy
5,391
+2,751
+104% +$37.9K ﹤0.01% 1355
2025
Q3 		$46K Buy
2,640
+633
+32% +$7.8K ﹤0.01% 1347
2025
Q2 		$19K Hold
2,007
– – ﹤0.01% 1360
2025
Q1 		$14K Sell
2,007
-181
-8% -$1.83K ﹤0.01% 1352
2024
Q4 		$26K Buy
2,188
+594
+37% +$9.27K ﹤0.01% 1328
2024
Q3 		$32K Sell
1,594
-594
-27% -$13.7K ﹤0.01% 1295
2024
Q2 		$49K Buy
2,188
+85
+4% +$2.02K ﹤0.01% 1286
2024
Q1 		$58K Buy
2,103
+161
+8% +$4.47K ﹤0.01% 1273
2023
Q4 		$59K Buy
1,942
+327
+20% +$9.4K ﹤0.01% 1276
2023
Q3 		$51K Sell
1,615
-82,927
-98% -$3.22M ﹤0.01% 1282
2023
Q2 		$3.45M Buy
84,542
+731
+0.9% +$29.6K 0.01% 600
2023
Q1 		$3.12M Sell
83,811
-9,879
-11% -$387K 0.01% 596
2022
Q4 		$3.27M Buy
93,690
+30,589
+48% +$1.45M 0.01% 568
2022
Q3 		$3.53M Sell
63,101
-21,855
-26% -$1.36M 0.01% 518
2022
Q2 		$4.4M Buy
84,956
+6,728
+9% +$342K 0.01% 489
2022
Q1 		$5.68M Sell
78,228
-1,656
-2% -$140K 0.01% 479
2021
Q4 		$9.45M Buy
79,884
+13,010
+19% +$1.63M 0.02% 385
2021
Q3 		$8.97M Buy
+66,874
New +$10.1M 0.02% 359

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

VanEck Associates's NTLA Position: Q1 2026 in Review

VanEck Associates reduced its Intellia Therapeutics (NTLA) stake by 14% in Q1 2026, selling an estimated $9.8K and leaving 4,622 shares worth $59K. The position accounts for ﹤0.01% of the portfolio, ranked #1327.

VanEck Associates first reported a position in NTLA in Q3 2021 and has held it in 19 quarters since. The position peaked at $9.45M in Q4 2021. 303 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • VanEck Associates held 4,622 shares of Intellia Therapeutics worth $59K as of Q1 2026.
  • VanEck Associates sold 769 Intellia Therapeutics shares in Q1 2026, an estimated $9.8K.
  • Intellia Therapeutics made up ﹤0.01% of VanEck Associates's portfolio in Q1 2026, its #1327 holding.
  • VanEck Associates first reported a position in Intellia Therapeutics in Q3 2021 and has held it in 19 quarters since.
  • VanEck Associates's Intellia Therapeutics position peaked at $9.45M in Q4 2021.
  • 303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on VanEck Associates's 13F filing for Q1 2026, filed 15 May 2026.